# Johnny Zou

> Johnny Zou is a Series A investor at Primavera Capital Group backing Biotechnology and Medical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Primavera Capital Group](https://shizune.co/investors/profile/primavera-capital)
- Total investments: 2
- Last investment: May 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/johnny-zou-2b5b0316/?originalSubdomain=hk

Johnny Zou is a Series A investor at Primavera Capital Group focused on Biotechnology and Medical. Johnny Zou is the Executive Director at Primavera Capital Group. He attended Yale University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Pharmaceutical | 1 | 50% |
| Artificial Intelligence | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Analytical Biosciences | Analytical Biosciences is a single-cell genome developer that aims to create and apply accurate maps of human diseases. In collaboration with medical research institutions, hospitals, and pharmaceutical companies, we are committed to exploiting the application of single-cell genomics and bioinformatics in the diagnosis and treatment of humandiseases. Through large-scale systematic disease single-cell mapping, big data intelligence mining is carried out to help a wide range of partners discover new therapeutic targets and develop new treatment strategies. |  | Series A | May 26, 2021 |  |
| Xbiome | Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to morequickly develop effective pharmaceuticals. |  | Series B | Nov 27, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 1 deal together
- [Green Pine Capital Partners](https://shizune.co/investors/profile/green-pine-capital-partners) — VC Fund, 1 deal together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 1 deal together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 1 deal together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 1 deal together
- [5Y Capital](https://shizune.co/investors/profile/morningsidevc) — VC Fund, 1 deal together

## About Primavera Capital Group

VC Fund · Beijing, China

Primavera Capital Group is a China-based global investment firm. With offices located in Beijing and Hong Kong, Primavera manages both RMB and USD funds for leading institutions, corporations, and families in China and around the world.Primavera Capital Group was founded by Dr. Fred Hu, a renowned economist and successful investor, and aformer partner and Chairman of Greater China at Goldman Sachs Group.The firm currently has 30+ investment professionals with an outstanding track record. The team combines global capital market experience, deep industry knowledge, and a unique network of relationships with policy-makers and regulators as well as leading CEOs and entrepreneurs in the region and globally.Primavera Capital Group puts great emphasis on rigorous fundamental research. The firm undertakes sophisticated analysis on economies, industries and companies to generate investment ideas, identify attractive opportunities, and guide its investment decisions.Primavera Capital Group employs a flexible investment strategy of growth capital, buy-out and control, and special situations - restructuring, distressed, and turn-arounds, etc.

5 contacts available at Primavera Capital Group.

| Name | Title | Profile |
| --- | --- | --- |
| David Lin | Managing Director | https://shizune.co/investors/profile/david-lin-4 |
| Fred Hu | Founder, Chairman & CEO | https://shizune.co/investors/profile/fred-hu |
| Johnny Zou | Executive Director | https://shizune.co/investors/profile/johnny-zou |
| Dapeng Zhu | Managing Director | https://shizune.co/investors/profile/dapeng-zhu-4735 |
| William Wang | Founding Partner | https://shizune.co/investors/profile/william-wang-98d4 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Johnny Zou invest in?

Johnny Zou invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Johnny Zou last invest?

The most recent investment recorded for Johnny Zou closed in May 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co